<https://www.dinet.org/forums/topic/21317-kinda-pissed-does-anyone-ever-find-peace/#comment-198628>
<http://schema.org/text>
"My neurologist diagnosed me with \"Chronic Daily Migraine/Transformed Migraine,\" which is by far my most disabling symptom.  Meds have not really proven effective for this or have stronger side effects than the headache.  I've had acupuncture for over a year, which helps, but has not solved the problem.  I am currently trying a \"back door\" route for my headaches that involves old foods and cutting edge science...alteration of the gut flora.  My current attempts are with Miso which contains kojic acid: Chem Pharm Bull (Tokyo). 2010 Oct;58(10):1353-61. \tKojic acid derivatives as histamine H(3) receptor ligands. Sander K, Kottke T, Weizel L, Stark H. \tSource Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, Biocenter, ZAFES/CMP/ICNF, Frankfurt/Main, Germany. \tAbstract The histamine H(3) receptor (H(3)R) is a promising target in the development of new compounds for the treatment of mainly centrally occurring diseases. However, emerging novel therapeutic concepts have been introduced and some indications in the H(3)R field, e.g. migraine, pain or allergic rhinitis, might take advantage of peripherally acting ligands. In this work, kojic acid-derived structural elements were inserted into a well established H(3)R antagonist/inverse agonist scaffold to investigate the bioisosteric potential of γ-pyranones with respect to the different moieties of the H(3)R pharmacophore. The most affine compounds showed receptor binding in the low nanomolar concentration range. Evaluation and comparison of kojic acid-containing ligands and their corresponding phenyl analogues (3-7) revealed that the newly integrated scaffold greatly influences chemical properties (S Log P, topological polar surface area (tPSA)) and hence, potentially modifies the pharmacokinetic profile of the different derivatives. Benzyl-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)methanamine ligands 3 and 4 belong to the centrally acting diamine-based class of H(3)R antagonist/inverse agonist, whereas kojic acid analogues 6 and 7 might act peripherally. The latter compounds state promising lead structures in the development of H(3)R ligands with a modified profile of action.\t\t\tPMID:\t\t\t20930404\t\t\t[PubMed - indexed for MEDLINE] "
<https://www.dinet.org/forums/topic/21317-kinda-pissed-does-anyone-ever-find-peace/?tab=comments#comment-198361>